|
The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers. |
|
|
Research Funding - Roche (Inst) |
|
|
Other Relationship - AstraZeneca (I); Bayer (I); Eisai (I); Illumina (I); Pfizer (I); Roche (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Bayer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Illumina (Inst); Pfizer (Inst); Roche (Inst) |